Bempegaldesleukin
- Generic Name
- Bempegaldesleukin
- Drug Type
- Biotech
- CAS Number
- 1939126-74-5
- Unique Ingredient Identifier
- BNO1JG5MZC
- Background
Bempegaldesleukin is under investigation in clinical trial NCT03729245 (A Study of NKTR-214 in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)).
A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2021-07-29
- Lead Sponsor
- Nektar Therapeutics
- Target Recruit Count
- 28
- Registration Number
- NCT02869295
- Locations
- 🇺🇸
Investigator Site - Portland, Portland, Oregon, United States
🇺🇸Investigator Site - New Haven, New Haven, Connecticut, United States
🇺🇸Investigator Site - Houston, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath